Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The National Bureau of Economic Research paper's lead author hopes putting a dollar value on the benefits of GLP-1s will lead to better access
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE:LLY) ranks among the most profitable blue chip stocks to buy according to hedge funds. Meanwhile, analysts see 9.20% upside for the stock. That outlook comes during a particularly active stretch of regulatory and clinical news for Lilly’s […]
We recently published Jim Cramer Didn’t Hold Back On SpaceX’s IPO & Discussed These 12 Stocks. Eli Lilly and Company (NYSE:LLY) is one of the stocks discussed by Jim Cramer. Healthcare and pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is one of Jim Cramer’s favorite stocks. Throughout 2025, the CNBC TV regularly praised the firm […]
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.
While the market fixates on the STELARA patent cliff, the rest of the business is quietly accelerating. Excluding the legacy drug, Johnson & Johnson (JNJ) grew in double digits for the quarter. The Innovative Medicine segment absorbed a massive 920 basis point headwind from STELARA, yet still posted 7.4% growth. This is not a company treading water, but a portfolio already hitting its next stride.
Eli Lilly (NYSE:LLY) has invested in Abridge, an AI-focused clinician documentation company. The partnership connects Lilly to Abridge's clinical conversation data platform, used across hundreds of health systems. The deal is aimed at using AI tools to speed up drug development, clinical trial enrollment, and evidence-based research. Eli Lilly is widely followed for its pharmaceutical portfolio, including obesity treatments and other therapies that have driven much of the recent discussion...
Thursday’s unusual options activity had plenty to choose from. However, it was the LEAPS that were really worth considering for bullish investors. Of the 28 calls over 365 days, these three quality stocks stood out.
With the massive SpaceX debut hogging the headlines, some retail investors may have allowed more prosaic names to slip from their minds. Pharma stock Eli Lilly is trading in a buy zone as institutional investors load up. Eli Lilly is committed to innovation and reinvests 20%-25% of its sales back into developing new treatments.
The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments.
Eli Lilly and Company (NYSE:LLY) is one of the 7 Best Compounder Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) plans to stop providing 340B discounted drug pricing to certain hospitals that have not complied with claims data reporting requirements introduced on February 1, Fierce Healthcare’s Dave Muoio reported. The move has drawn opposition […]
Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here’s what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
Eli Lilly and Company (NYSE:LLY) rose around 12% in May 2026, primarily driven by strong FQ1 2026 earnings beat and FDA approval for Foundayo and expansion of insurance coverage of obesity treatment. With 132 hedge funds holding the stock as of Q1 2026, Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to […]
(Updates with Eli Lilly's response to a request for comment from MT Newswires.) Some employers in
There are already lengthy patient waitlists for the medication on digital health platforms.
The company is working with Nvidia to build a foundation model for clinical conversations, and it scored a strategic investment from drugmaker Eli Lilly, Abridge announced during a sweeping keynote Thursday.
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy, according to analysts. On June 7, Eli Lilly and Company (NYSE:LLY) announced top-line results for Foundayo (orforglipron), the only oral GLP-1 that can be taken without food or water restrictions. Clinical trial results showed that women with obesity and who were […]
Investing.com -- Elon Musk’s SpaceX on Thursday said that it has priced its initial public offering at $135 per share on Thursday, raising $75 billion in the largest IPO in U.S. history.
Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street
Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) reported Q1 2026 results that pulled the GLP-1 duopoly apart. Lilly grew revenue 55.5% and raised guidance. Novo posted a 4% adjusted sales decline at constant currency and is cutting 9,000 jobs. Both call obesity the prize, but their quarters tell very different stories about who ... Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
The $5.3 billion ambient AI startup is expanding from clinical notes into billing, drug trials, and real-time insurance claims.
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Rising use of weight-loss drugs keeps pressure on health benefit costs.
ABBV's Skyrizi and Rinvoq post strong Q1 growth, lift 2026 sales outlooks and sustain momentum through new indications.
The AI boom has been built on a simple assumption: the companies with the best models will capture most of the value. That belief helped push valuations for leading AI developers into the hundreds of billions of dollars and turned model performance benchmarks into headline news. But markets have a habit of changing the rules. ... An AI Price War Is About to Break Out. You Won’t Believe Who Will Profit Most
Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
